Bungie announced the Destiny 2: The Final Shape expansion will launch on February 27, 2024 and the latest season [...]
While Eramis' plans were thwarted and the relics of Nezarec's body destroyed, Nezarec has a presence in Neomuna with the Lightfall expansion. Nezarec's haunting whispers can be heard while walking around the location. Furthermore, if you equip either the Nezarec's Sin Exotic Warlock helmet...
WithThe Final Shapeexpansion pack around the corner, you might want to customize your character’s appearance with Emblems and Shaders. So here’s a list of all Destiny 2 codes in May 2024. All Destiny 2 codes for Emblems in May 2024 ...
One of Bungie's top community managers has asked Destiny 2 fans to suggest more quality of life changes they want to see in Lightfall and beyondJamie Hore Published: Jan 12, 2023 Destiny 2 Destiny 2 Lightfall is creeping ever closer, and while the new expansion will add a stunning ...
T-DXd在HER2阳性晚期乳腺癌应用的适应症主要源于DESTINY-Breast03研究中T-DXd与恩美曲妥珠单抗(T-DM1)的头对头比较,结果显示T-DXd vs T-DM1的中位无进展生存期(PFS)为28.8个月vs 6.8个月[1],2024年美国临床肿瘤学会(ASCO)更新的中...
DG-03 Part 2 (dose expansion; NCT04379596) enrolled pts with 1L HER2+ (immunohistochemistry [IHC] 3+ or IHC 2+/in situ hybridization-positive by local testing) esophageal/gastric/GEJA globally, irrespective of PD-L1 sta...
DESTINY-Breast07 is a Phase 1b/2 multicenter, open-label, modular study exploring the safety, tolerability, and antitumor activity of T-DXd alone or in combination with other anticancer agents (NCT04538742). These results are from an interim analysis of the dose-expansion phase assessing T-DXd...
[7]. Andre F, Hamilton E P, Loi S, et al. DESTINY-Breast07: Dose-expansion interim analysis of T-DXd monotherapy and T-DXd+ pertuzumab in patients with previously untreated HER2+ mBC[J]. J Clin Oncol, 2024, 42(16_suppl): 1009. ...
2.斯锦棐,等. HER2基因突变晚期非小细胞肺癌治疗进展[J]. 肿瘤药学. 2023; 13(4): 395-406. 3.Tsurutani J,et al. Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors. Cancer Discov. 2020 May;10(5):688-701. 4.Li BT,et al. Ph...
T-DXd在HER2阳性晚期乳腺癌应用的适应症主要源于DESTINY-Breast03研究中T-DXd与恩美曲妥珠单抗(T-DM1)的头对头比较,结果显示T-DXd vs T-DM1的中位无进展生存期(PFS)为28.8个月vs 6.8个月[1],2024年美国临床肿瘤学会(ASCO)更新的中位生存期(OS)为52.6个月 vs 42.7个月[2]。